ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC lowered its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 15.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 180,578 shares of the specialty pharmaceutical company’s stock after selling 32,252 shares during the period. Mizuho Markets Americas LLC’s holdings in ANI Pharmaceuticals were worth $16,541,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Global Alpha Capital Management Ltd. lifted its holdings in ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after acquiring an additional 126,500 shares during the last quarter. Rubric Capital Management LP lifted its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in ANI Pharmaceuticals by 6.4% during the second quarter. Loomis Sayles & Co. L P now owns 206,382 shares of the specialty pharmaceutical company’s stock valued at $13,466,000 after purchasing an additional 12,494 shares during the last quarter. Bank of America Corp DE boosted its holdings in ANI Pharmaceuticals by 32.0% during the second quarter. Bank of America Corp DE now owns 185,465 shares of the specialty pharmaceutical company’s stock worth $12,102,000 after buying an additional 44,916 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in ANI Pharmaceuticals by 3,156.3% in the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock worth $9,617,000 after buying an additional 142,854 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $84.83 on Monday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 52.04 and a beta of 0.51. The company has a 50 day simple moving average of $82.01 and a 200-day simple moving average of $83.97. ANI Pharmaceuticals, Inc. has a 52-week low of $54.10 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period in the previous year, the firm posted $1.34 earnings per share. The firm’s revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several research reports. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $103.43.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares of the company’s stock, valued at approximately $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chad Gassert sold 14,642 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the transaction, the senior vice president owned 158,584 shares in the company, valued at $14,125,076.88. This trade represents a 8.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 28,101 shares of company stock valued at $2,453,063 in the last three months. Company insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.